异基因脐带血干细胞治疗重度脑瘫患者的安全性：一项回顾性研究。
Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study.
作者信息
Feng Mei, Lu Aili, Gao Hongxia, Qian Caiwen, Zhang Jun, Lin Tongxiang, Zhao Yuanqi
机构信息
Department of General Internal Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China.
The School of Medicine, Jinan University, Guangzhou 510632, China ; Shenzhen Beike Cell Engineering Research Institute, Shenzhen 518057, China.
出版信息
Stem Cells Int. 2015;2015:325652. doi: 10.1155/2015/325652. Epub 2015 Jul 8.
This retrospective study aimed to assess the safety of patients with severe cerebral palsy (CP), who received allogeneic umbilical cord blood stem cells (UCBSCs) treatment from August 2009 to December 2012 in Guangdong Provincial Hospital of Chinese Medicine. A total of 47 patients with average age of 5.85 ± 6.12 years were evaluated in this study. There was no significant association with allogeneic UCBSCs treatments found in the data of the laboratory index . No casualties occurred. Some adverse events during treatments were found in 26 (55.3%) patients, including fever (42.6%) and vomiting (21.2%). Intrathecal infusion and the ages at the initiation of treatment (≤10 years old) were risk factors for the occurrence of adverse events by logistic regression analysis. However, all adverse events disappeared after symptomatic treatment. No treatment related serious adverse events were found in follow-up visits within 6 months. In conclusion, allogeneic UCBSCs treatment was relatively safe for severe CP patients.
这项回顾性研究旨在评估2009年8月至2012年12月期间在广东省中医院接受异基因脐带血干细胞（UCBSCs）治疗的重度脑瘫（CP）患者的安全性。本研究共评估了47例平均年龄为5.85±6.12岁的患者。实验室指标数据中未发现与异基因UCBSCs治疗有显著关联。未发生死亡病例。26例（55.3%）患者在治疗期间出现了一些不良事件，包括发热（42.6%）和呕吐（21.2%）。经逻辑回归分析，鞘内注射和治疗开始时的年龄（≤10岁）是不良事件发生的危险因素。然而，所有不良事件经对症治疗后均消失。在6个月的随访中未发现与治疗相关的严重不良事件。总之，异基因UCBSCs治疗对重度CP患者相对安全。
Zotero 插件